WEP Clinical LTD (WEP), a specialist services company that works with pharmaceutical companies to help patients and physicians gain access to medicines when no other treatment options are available, has partnered with Theratechnologies Inc. to launch a Named Patient Program (NPP) for EGRIFTA SV® (tesamorelin), a treatment indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
The NPP is designed to ensure that physicians in Western Europe (Belgium, France, Germany, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain), Nordic Region (Denmark, Finland, Iceland, Norway, Sweden), and United Kingdom (England, Wales, Scotland, Northern Ireland), where EGRIFTA SV® has not received regulatory approval, can request access to the product on behalf of individual patients living with HIV who have changes in the way their body fat is distributed and wish to have the excess fat in the stomach area (abdomen) reduced.
Jas Khera, Managing Director of WEP, said:
“We are thrilled to be able to partner with Theratechnologies to help ensure broader access to EGRIFTA SV®. This is the second Named Patient Program that WEP Clinical is making available to patients living with HIV, and we are proud to be able to continue to serve this patient community.”
For physicians who are interested in further information on the EGRIFTA SV® Named Patient Program, please contact: egrifta@wepclinical.com.
About EGRIFTA SV®
EGRIFTA SV® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Limitations of use:
- Long-term cardiovascular safety of EGRIFTA SV® has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue.
- EGRIFTA SV® is not indicated for weight loss management as it has a weight neutral effect.
- There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV®.
Lipodystrophy affects the redistribution of fat that includes the accumulation and loss of fat in certain parts of the human body. The excess fat accumulating in the abdomen due to lipodystrophy is called visceral fat. Often, visceral fat is mistaken for subcutaneous fat. Unlike subcutaneous fat, visceral fat lies deeper in the abdomen area. It is harder and firmer than subcutaneous fat which is soft and squishy. Visceral fat can be difficult to control with diet and exercise alone.
About WEP
At WEP Clinical, we are With Every Patient, as we believe every patient should have access to treatment! With this as our guiding principle, we have created a market leading, solutions driven, healthcare services company that partners with drug developers to create broader treatment access solutions for patients worldwide. We take pride in the high-quality output and positive customer experience we create while delivering our services. We specialize in the following: Expanded Access and Post-Approval Named Patient Programs; Market Access Solutions; Home Nursing Services for Decentralized Clinical Trials; and Clinical Trial Sourcing. For more information, please visit www.wepclinical.com.
